Clinical trial
A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD…
NCT00376168 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00376168 |
|---|---|
| Title | A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease |
| Official title | A Phase III, Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gaucher Disease |
| Intervention type | Drug |
| Interventions | Plant cell expressed recombinant glucocerebrosidase (prGCD) |
| Enrollment | 32 |
| Start date | Aug 1, 2007 |
| Primary completion | Sep 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Sep 14, 2006 |
| Last update posted | Oct 4, 2018 |
| Countries | Canada, Chile, Israel, Italy, South Africa, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: